Protocol treatment and NK expansion schema. (A) Treatment schema. Asterisk denotes time point that was delayed to days (D) 15 and 24 to meet Food and Drug Administration–mandated regulatory requirements for subjects 1 and 2, respectively. (B) Processing of filgrastim-mobilized peripheral blood stem cells to yield a T cell–depleted PBSC graft and a T cell–depleted, activated NK donor leukocyte infusion (aNK-DLI). G-CSF, granulocyte macrophage colony-stimulating factor; TCD, T-cell–depleted; Wk, week.